The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

dc.contributor.author	Обертинська, О.Г.
dc.contributor.author	Obertynska, O.
dc.date.accessioned	2025-03-23T16:35:21Z
dc.date.available	2025-03-23T16:35:21Z
dc.date.issued	2021
dc.identifier.citation	Obertynska O. The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease / O. Obertynska // EUROPEAN HEART JOURNAL. – 2021. – № 42 (suppl. 1). – P. 895.	uk_UA
dc.identifier.issn	0195-668X
dc.identifier.uri	https://dspace.vnmu.edu.ua/123456789/8796
dc.description.abstract	Mineralocorticoid receptor antagonists (MRAs) remain underused in cases of heart failure with a reduced left ventricular ejection fraction (HFrEF) and chronic kidney disease (CKD), largely due to the fear of inducing worsening of renal function (RF) and hyperkalemia (HK), particularly in combination with renin angiotensin inhibitors.	uk_UA
dc.language.iso	uk_UA_	uk_UA
dc.publisher	European Society of Cardiology	uk_UA
dc.subject	spironolactone	uk_UA
dc.subject	heart failure	uk_UA
dc.subject	chronic kidney disease	uk_UA
dc.title	The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease	uk_UA
dc.type	Thesis	uk_UA